Tizanidine hydrochloride
SIGMA/T6950 - ≥98% (HPLC), powder
Synonym: 5-
CAS Number: 64461-82-1
Empirical Formula (Hill Notation): C9H9Cl2N5S
Molecular Weight: 290.17
MDL Number: MFCD00798231
Linear Formula: C9H9Cl2N5S
Product Type: Chemical
| assay | ≥98% (HPLC) |
| color | white |
| form | powder |
| InChI | 1S/C9H8ClN5S.ClH/c10-5-1- |
| InChI key | ZWUKMNZJRDGCTQ-UHFFFAOYSA |
| originator | Acorda Therapeutics |
| Quality Level | 100  |
| SMILES string | Cl[H].Clc1ccc2nsnc2c1NC3= |
| solubility | H2O: >20 mg/mL |
| Application: | Tizanidine hydrochloride has been used for developing spectrophotometric methods for the validation of skeletal muscle relaxants. |
| Biochem/physiol Actions: | α2-adrenoceptor agonist. |
| Biochem/physiol Actions: | Tizanidine hydrochloride is known to function as a skeletal muscle relaxant that acts centrally. Furthermore, this relaxant functions at spinal and supraspinal levels to block excitatory interneurons. This drug is used for the symptomatic relief of spasticity and painful muscle spasms. |
| Features and Benefits: | This compound was developed by Acorda Therapeutics . To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here . |
| Packaging: | 10, 50 mg in glass bottle |
| Preparation Note: | Tizanidine hydrochloride is soluble in water at a concentration that is greater than 20 mg/ml. |
| Symbol |  GHS07 |
| Signal word | Warning |
| Hazard statements | H302 - H315 - H319 - H335 |
| Precautionary statements | P301 + P312 + P330 - P302 + P352 - P305 + P351 + P338 |
| Hazard Codes | Xn |
| Risk Statements | 22-36/37/38 |
| Safety Statements | 26-36 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥98% (HPLC) |
| UNSPSC | 12352200 |